Enhancing aromatic L-amino acid decarboxylase activity: Implications for L-DOPA treatment in Parkinson's disease

CNS Neuroscience and Therapeutics

Volumn 14, Issue 4, 2008, Pages 340-351

  Hadjiconstantinou, Maria ^a   Neff, Norton H ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Aromatic L amino acid decarboxylase; L DOPA; L DOPA decarboxylation; Neurotransmitter receptors; Parkinson's disease; Striatum

Indexed keywords

2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 3 [[4 (4 CHLOROPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE; 5,5 DIMETHYL 2 MORPHOLINEACETIC ACID; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AROMATIC LEVO AMINO ACID DECARBOXYLASE; BROMOCRIPTINE; CLONIDINE; CLORGYLINE; CLOZAPINE; DIZOCILPINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; FLUPENTIXOL; HALOPERIDOL; LEVODOPA; METHOXAMINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NICOTINIC RECEPTOR; PARGYLINE; PIMOZIDE; PRAZOSIN; QUINPIROLE; R HA 966; REMOXIPRIDE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SPIPERONE; SULPIRIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; YOHIMBINE;

CORPUS STRIATUM; DECARBOXYLATION; DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; HUMAN; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; REVIEW; SECOND MESSENGER;

ANIMALS; AROMATIC-L-AMINO-ACID DECARBOXYLASES; CORPUS STRIATUM; DECARBOXYLATION; HUMANS; LEVODOPA; PARKINSON DISEASE; RECEPTORS, DOPAMINE;

EID: 56049085197     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2008.00058.x     Document Type: Review

References (119)

1. Holtz P, Heise R, Ludtke K. Fermentativer Abbau von L-Dioxyphenylalanin (Dopa) durch Niere. Naunyn Schmiedeberg's Arch exp Path Pharmak 1938 191 : 87 118.
2. Birkmayer W, Hornykiewicz O The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wien Klin Wochenschr 1961 73 : 787 788.
3. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of Parkinsonism. N Engl J Med 1967 276 : 374 379.
4. Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of Parkinsonism with levodopa. Arch Neurol 1969 21 : 343 354.
5. Berry MD, Juorio AV, Li XM, Boulton AA. Aromatic L-amino acid decarboxylase: A neglected and misunderstood enzyme. Neurochem Res 1996 21 : 1075 1087.
6. Hadjiconstantinou M, Rossetti Z, Silvia C, Krajnc D, Neff NH. Aromatic L-amino acid decarboxylase activity of the rat retina is modulated in vivo by environmental light. J Neurochem 1988 51 : 1560 1564.
7. Hadjiconstantinou M, Wemlinger TA, Sylvia CP, Hubble JP, Neff NH. Aromatic L-amino acid decarboxylase activity of mouse striatum is modulated via dopamine receptors. J Neurochem 1993 60 : 2175 2180.
8. Rossetti Z, Krajnc D, Neff NH, Hadjiconstantinou M. Modulation of retinal aromatic L-amino acid decarboxylase via alpha 2 adrenoceptors. J Neurochem 1989 52 : 647 652.
9. Zhu MY, Juorio AV, Paterson IA, Boulton AA. Regulation of aromatic L-amino acid decarboxylase by dopamine receptors in the rat brain. J Neurochem 1992 58 : 636 641.
10. Young EA, Duchemin AM, Neff NH, Hadjiconstantinou M. Parallel modulation of striatal dopamine synthetic enzymes by second messenger pathways. Eur J Pharmacol 1998 357 : 15 23.
11. Young EA, Neff NH, Hadjiconstantinou M. Phorbol ester administration transiently increases aromatic L-amino acid decarboxylase activity of the mouse striatum and midbrain. J Neurochem 1994 63 : 694 697.
12. Young EA, Neff NH, Hadjiconstantinou M. Evidence for cyclic AMP-mediated increase of aromatic L-amino acid decarboxylase activity in the striatum and midbrain. J Neurochem 1993 60 : 2331 2333.
13. Cho S, Neff NH, Hadjiconstantinou M. Regulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase by dopaminergic drugs. Eur J Pharmacol 1997 323 : 149 157.
14. Fisher A, Biggs CS, Starr MS. Differential effects of NMDA and non-NMDA antagonists on the activity of aromatic L-amino acid decarboxylase activity in the nigrostriatal dopamine pathway of the rat. Brain Res 1998 792 : 126 132.
15. Fisher A, Biggs CS, Starr MS. Effects of glutamate antagonists on the activity of aromatic L-amino acid decarboxylase. Amino Acids 1998 14 : 43 49.
16. Fisher A, Starr MS. Opposite effects of glutamate antagonists and antiparkinsonian drugs on the activities of DOPA decarboxylase and 5-HTP decarboxylase in the rat brain. Brain Res 2000 868 : 268 274.
17. Tehranian R, Montoya SE, van Laar AD, Hastings TG, Perez RG. Alpha-synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells. J Neurochem 2006 99 : 1188 1196.
18. Duchemin AM, Berry MD, Neff NH, Hadjiconstantinou M. Phosphorylation and activation of brain aromatic L-amino acid decarboxylase by cyclic AMP-dependent protein kinase. J Neurochem 2000 75 : 725 731.
19. Neff NH, Wemlinger TA, Duchemin AM, Hadjiconstantinou M. Clozapine modulates aromatic L-amino acid decarboxylase activity in mouse striatum. J Pharmacol Exp Ther 2006 317 : 480 487.
20. Cho S, Duchemin AM, Neff NH, Hadjiconstantinou M. Tyrosine hydroxylase, aromatic L-amino acid decarboxylase and dopamine metabolism after chronic treatment with dopaminergic drugs. Brain Res 1999 830 : 237 245.
21. Aguanno A, Lee MR, Marden CM, Rattray M, Gault A, Albert VR. Analysis of the neuronal promoter of the rat aromatic L-amino acid decarboxylase gene. J Neurochem 1995 65 : 1944 1954.
22. Hahn SL, Hahn M, Kang UJ, Joh TH. Structure of the rat aromatic L-amino acid decarboxylase gene: Evidence for an alternative promoter usage. J Neurochem 1993 60 : 1058 1064.
23. O'Malley KL, Harmon S, Moffat M, Uhland-Smith A, Wong S. The human aromatic L-amino acid decarboxylase gene can be alternatively spliced to generate unique protein isoforms. J Neurochem 1995 65 : 2409 2416.
24. Wessel TC, Joh TH. Parallel upregulation of catecholamine-synthesizing enzymes in rat brain and adrenal gland: Effects of reserpine and correlation with immediate early gene expression. Brain Res Mol Brain Res 1992 15 : 349 360.
25. Li XM, Juorio AV, Boulton AA. NSD-1015 alters the gene expression of aromatic L-amino acid decarboxylase in rat PC12 pheochromocytoma cells. Neurochem Res 1993 18 : 915 919.
26. Li XM, Juorio AV, Boulton AA. Induction of aromatic L-amino acid decarboxylase mRNA by interleukin-1 beta and prostaglandin E2 in PC12 cells. Neurochem Res 1994 19 : 591 595.
27. Li XM, Juorio AV, Paterson IA, Zhu MY, Boulton AA. Specific irreversible monoamine oxidase B inhibitors stimulate gene expression of aromatic L-amino acid decarboxylase in PC12 cells. J Neurochem 1992 59 : 2324 2327.
28. Kim KT, Park DH, Joh TH. Parallel up-regulation of catecholamine biosynthetic enzymes by dexamethasone in PC12 cells. J Neurochem 1993 60 : 946 951.
29. Hadjiconstantinou M, Neff NH, Zhou LW, Weiss B. D2 dopamine receptor antisense increases the activity and mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in mouse brain. Neurosci Lett 1996 217 : 105 108.
30. Hadjiconstantinou M, Rossetti ZL, Wemlinger TA, Neff NH. Dizocilpine enhances striatal tyrosine hydroxylase and aromatic L-amino acid decarboxylase activity. Eur J Pharmacol 1995 289 : 97 101.
31. Cho S, Duchemin AM, Neff NH, Hadjiconstantinou M. Modulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase after inhibiting monoamine oxidase-A. Eur J Pharmacol 1996 314 : 51 59.
32. Baptista MJ, O'Farrell C, Daya S, Ahmad R, Miller DW, Hardy J, Farrer MJ, Cookson MR. Co-ordinate transcriptional regulation of dopamine synthesis genes by alpha-synuclein in human neuroblastoma cell lines. J Neurochem 2003 85 : 957 968.
33. Tashiro Y, Kaneko T, Sugimoto T, Nagatsu I, Kikuchi H, Mizuno N. Striatal neurons with aromatic L-amino acid decarboxylase-like immunoreactivity in the rat. Neurosci Lett 1989 100 : 29 34.
34. Eaton MJ, Gudehithlu KP, Quach T, Silvia CP, Hadjiconstantinou M, Neff NH. Distribution of aromatic L-amino acid decarboxylase mRNA in mouse brain by in situ hybridization histology. J Comp Neurol 1993 337 : 640 654.
35. Meredith GE, Farrell T, Kellaghan P, Tan Y, Zahm DS, Totterdell S. Immunocytochemical characterization of catecholaminergic neurons in the rat striatum following dopamine-depleting lesions. Eur J Neurosci 1999 11 : 3585 3596.
36. Zhu MY, Juorio AV, Paterson IA, Boulton AA. Regulation of striatal aromatic L-amino acid decarboxylase: Effects of blockade or activation of dopamine receptors. Eur J Pharmacol 1993 238 : 157 164.
37. Buckland PR, O'Donovan MC, McGuffin P. Changes in dopa decarboxylase mRNA but not tyrosine hydroxylase mRNA levels in rat brain following antipsychotic treatment. Psychopharmacology (Berl) 1992 108 : 98 102.
38. Elkashef AM, Doudet D, Bryant T, Cohen RM, Li SH, Wyatt RJ. 6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography. Psychiatry Res 2000 100 : 1 11.
39. Biggs CS, Fisher A, Starr MS. The antiparkinsonian drug budipine stimulates the activity of aromatic L-amino acid decarboxylase and enhances L-DOPA-induced dopamine release in rat substantia nigra. Synapse 1998 30 : 309 317.
40. Fisher A, Biggs CS, Eradiri O, Starr MS. Dual effects of L-3,4-dihydroxyphenylalanine on aromatic L-amino acid decarboxylase, dopamine release and motor stimulation in the reserpine-treated rat: Evidence that behaviour is dopamine independent. Neuroscience 2000 95 : 97 111.
41. Cumming P, Kuwabara H, Ase A, Gjedde A. Regulation of DOPA decarboxylase activity in brain of living rat. J Neurochem 1995 65 : 1381 1390.
42. Cumming P, Ase A, Laliberte C, Kuwabara H, Gjedde A. In vivo regulation of DOPA decarboxylase by dopamine receptors in rat brain. J Cereb Blood Flow Metab 1997 17 : 1254 1260.
43. Vernaleken I, Kumakura Y, Cumming P, Buchholz HG, Siessmeier T, Stoeter P, et al. Modulation of [18F]fluorodopa (FDOPA) kinetics in the brain of healthy volunteers after acute haloperidol challenge. Neuroimage 2006 30 : 1332 1339.
44. Danielsen EH, Smith D, Hermansen F, Gjedde A, Cumming P. Acute neuroleptic stimulates DOPA decarboxylase in porcine brain in vivo. Synapse 2001 41 : 172 175.
45. DeJesus OT, Flores LG, Roberts AD, Dick DW, Bartlett RM, Murali D, et al. Aromatic L-amino acid decarboxylase (AAAD) activity in rhesus macaque striatum after MAO-B inhibition by Ro 16-6491. Synapse 2005 56 : 54 56.
46. Laakso A, Pohjalainen T, Bergman J, Kajander J, Haaparanta M, Solin O, et al. The A1 allele of the human D2 dopamine receptor gene is associated with increased activity of striatal L-amino acid decarboxylase in healthy subjects. Pharmacogenet Genomics 2005 15 : 387 391.
47. Buckland PR, Marshall R, Watkins P, McGuffin P. Does phenylethylamine have a role in schizophrenia?: LSD and PCP up-regulate aromatic L-amino acid decarboxylase mRNA levels. Brain Res Mol Brain Res 1997 49 : 266 270.
48. Zigmond MJ, Castro SL, Keefe KA, Abercrombie ED, Sved AF. Role of excitatory amino acids in the regulation of dopamine synthesis and release in the neostriatum. Amino Acids 1998 14 : 57 62.
49. David HN, Ansseau M, Abraini JH. Dopamine-glutamate reciprocal modulation of release and motor responses in the rat caudate-putamen and nucleus accumbens of "intact" animals. Brain Res Brain Res Rev 2005 50 : 336 360.
50. Alex KD, Pehek EA. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 2007 113 : 296 320.
51. Bustos G, Abarca J, Campusano J, Bustos V, Noriega V, Aliaga E. Functional interactions between somatodendritic dopamine release, glutamate receptors and brain-derived neurotrophic factor expression in mesencephalic structures of the brain. Brain Res Brain Res Rev 2004 47 : 126 144.
52. Xu JA, Hadjiconstantinou M, Neff NH. Exposure to light accelerates the formation of dopamine from exogenous L-dopa in the rat retina. J Ocul Pharmacol 1985 1 : 177 181.
53. Neff NH, Wemlinger TA, Hadjiconstantinou M. SCH 23390 enhances exogenous L-DOPA decarboxylation in nigrostriatal neurons. J Neural Transm 2000 107 : 429 443.
54. Biggs CS, Starr MS. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum. Synapse 1999 34 : 36 46.
55. Reith J, Cumming P, Gjedde A. Enhanced [3H]DOPA and [3H]dopamine turnover in striatum and frontal cortex in vivo linked to glutamate receptor antagonism. J Neurochem 1998 70 : 1979 1985.
56. Deep P, Dagher A, Sadikot A, Gjedde A, Cumming P. Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine. Synapse 1999 34 : 313 318.
57. Melamed E, Hefti F, Wurtman RJ. Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in Parkinsonism. Ann Neurol 1980 8 : 558 563.
58. Tison F, Mons N, Geffard M, Henry P. The metabolism of exogenous L-dopa in the brain: An immunohistochemical study of its conversion to dopamine in non-catecholaminergic cells of the rat brain. J Neural Transm Park Dis Dement Sect 1991 3 : 27 39.
59. Mura A, Jackson D, Manley MS, Young SJ, Groves PM. Aromatic L-amino acid decarboxylase immunoreactive cells in the rat striatum: A possible site for the conversion of exogenous L-DOPA to dopamine. Brain Res 1995 704 : 51 60.
60. Brown WD, Taylor MD, Roberts AD, Oakes TR, Schueller MJ, Holden JE, et al. FluoroDOPA PET shows the nondopaminergic as well as dopaminergic destinations of levodopa. Neurology 1999 53 : 1212 1218.
61. Lopez A, Munoz A, Guerra MJ, Labandeira-Garcia JL. Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum. Neuroscience 2001 103 : 639 651.
62. Lopez-Real A, Rodriguez-Pallares J, Guerra MJ, Labandeira-Garcia JL. Localization and functional significance of striatal neurons immunoreactive to aromatic L-amino acid decarboxylase or tyrosine hydroxylase in rat Parkinsonian models. Brain Res 2003 969 : 135 146.
63. Maeda T, Nagata K, Yoshida Y, Kannari K. Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPA. Brain Res 2005 1046 : 230 233.
64. Hadjiconstantinou M, Neff NH. Differential recovery of dopamine synthetic enzymes following MPTP and the consequences of GM1 ganglioside treatment. Eur J Pharmacol 1990 181 : 137 139.
65. Jonkers N, Sarre S, Ebinger G, Michotte Y. MK801 influences L-DOPA-induced dopamine release in intact and hemi-Parkinson rats. Eur J Pharmacol 2000 407 : 281 291.
66. Arai A, Kannari K, Shen H, Maeda T, Suda T, Matsunaga M. Amantadine increases L-DOPA-derived extracellular dopamine in the striatum of 6-hydroxydopamine-lesioned rats. Brain Res 2003 972 : 229 234.
67. Heiss WD, Hilker R. The sensitivity of 18-fluorodopa positron emission tomography and magnetic resonance imaging in Parkinson's disease. Eur J Neurol 2004 11 : 5 12.
68. Ravina B, Eidelberg D, Ahlskog JE, Albin RL, Brooks DJ, Carbon M, et al. The role of radiotracer imaging in Parkinson disease. Neurology 2005 64 : 208 215.
69. Kuwabara H, Cumming P, Yasuhara Y, Leger GC, Guttman M, Diksic M, et al. Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease. J Nucl Med 1995 36 : 1226 1231.
70. Morrish PK, Sawle GV, Brooks DJ. Clinical and [18F] dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry 1995 59 : 597 600.
71. Rakshi JS, Uema T, Ito K, Bailey DL, Morrish PK, Ashburner J, et al. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study. Brain 1999 122 (Pt 9 1637 1650.
72. Bruck A, Aalto S, Nurmi E, Vahlberg T, Bergman J, Rinne JO. Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: A two-year follow-up study. Mov Disord 2006 21 : 958 963.
73. Moore RY, Whone AL, Brooks DJ. Extrastriatal monoamine neuron function in Parkinson's disease: An 18F-dopa PET study. Neurobiol Dis 2008 29 : 381 390.
74. Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 2000 47 : 493 503.
75. Tedroff J, Ekesbo A, Rydin E, Langstrom B, Hagberg G. Regulation of dopaminergic activity in early Parkinson's disease. Ann Neurol 1999 46 : 359 365.
76. Whone AL, Moore RY, Piccini PP, Brooks DJ. Plasticity of the nigropallidal pathway in Parkinson's disease. Ann Neurol 2003 53 : 206 213.
77. Brooks DJ, Piccini P. Imaging in Parkinson's disease: The role of monoamines in behavior. Biol Psychiatry 2006 59 : 908 918.
78. Torstenson R, Hartvig P, Langstrom B, Westerberg G, Tedroff J. Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease. Ann Neurol 1997 41 : 334 340.
79. Ekesbo A, Rydin E, Torstenson R, Sydow O, Laengstrom B, Tedroff J. Dopamine autoreceptor function is lost in advanced Parkinson's disease. Neurology 1999 52 : 120 125.
80. Ceravolo R, Piccini P, Bailey DL, Jorga KM, Bryson H, Brooks DJ. 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. Synapse 2002 43 : 201 207.
81. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003 54 : 93 101.
82. Rakshi JS, Pavese N, Uema T, Ito K, Morrish PK, Bailey DL, et al. A comparison of the progression of early Parkinson's disease in patients started on ropinirole or L-dopa: An 18F-dopa PET study. J Neural Transm 2002 109 : 1433 1443.
83. Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996 119 (Pt 2 585 591.
84. Nurmi E, Ruottinen HM, Bergman J, Haaparanta M, Solin O, Sonninen P, et al. Rate of progression in Parkinson's disease: A 6-[18F]fluoro-L-dopa PET study. Mov Disord 2001 16 : 608 615.
85. Nurmi E, Bergman J, Eskola O, Solin O, Vahlberg T, Sonninen P, et al. Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET. Synapse 2003 48 : 109 115.
86. Koller WC. Treatment of early Parkinson's disease. Neurology 2002 58 : S79 S86.
87. Olanow W, Schapira AH, Rascol O. Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends Neurosci 2000 23 : S117 S126.
88. Chase TN. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs 1998 55 (Suppl. 1 1 9.
89. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000 123 (Pt 11 2297 2305.
90. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004 351 : 2498 2508.
91. Stocchi F, Olanow CW. Continuous dopaminergic stimulation in early and advanced Parkinson's disease. Neurology 2004 62 : S56 S63.
92. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 1998 64 : 314 319.
93. Jellinger K, Bliesath H. Adjuvant treatment of Parksinson's disease with budipine: A double-blind trial versus placebo. J Neurol 1987 234 : 280 282.
94. Merello M, Nouzeilles MI, Cammarota A, Leiguarda R. Effect of memantine (NMDA antagonist) on Parkinson's disease: A double-blind crossover randomized study. Clin Neuropharmacol 1999 22 : 273 276.
95. Rabey JM, Nissipeanu P, Korczyn AD. Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. J Neural Transm Park Dis Dement Sect 1992 4 : 277 282.
96. Przuntek H, Bittkau S, Bliesath H, Buttner U, Fuchs G, Glass J, et al. Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen. Arch Neurol 2002 59 : 803 806.
97. Crosby N, Deane KH, Clarke CE. Amantadine in Parkinson's disease. Cochrane Database Syst Rev 2003 : CD003468.
98. Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005 20 : 523 539.
99. Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa-induced dyskinesias. Mov Disord 2007 22 : 1379 1389 quiz 523.
100. Factor SA, Brown D. Clozapine prevents recurrence of psychosis in Parkinson's disease. Mov Disord 1992 7 : 125 131.
101. Linazasoro G, Marti Masso JF, Suarez JA. Nocturnal akathisia in Parkinson's disease: Treatment with clozapine. Mov Disord 1993 8 : 171 174.
102. Bennett JP, Jr., Landow ER, Dietrich S, Schuh LA. Suppression of dyskinesias in advanced Parkinson's disease: Moderate daily clozapine doses provide long-term dyskinesia reduction. Mov Disord 1994 9 : 409 414.
103. Wagner ML, Defilippi JL, Menza MA, Sage JI. Clozapine for the treatment of psychosis in Parkinson's disease: Chart review of 49 patients. J Neuropsychiatry Clin Neurosci 1996 8 : 276 280.
104. Trosch RM, Friedman JH, Lannon MC, Pahwa R, Smith D, Seeberger LC, et al. Clozapine use in Parkinson's disease: A retrospective analysis of a large multicentered clinical experience. Mov Disord 1998 13 : 377 382.
105. Ellis T, Cudkowicz ME, Sexton PM, Growdon JH. Clozapine and risperidone treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2000 12 : 364 369.
106. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: Comparative effects on motor function in hallucinating PD patients. Neurology 2000 55 : 789 794.
107. Morgante L, Epifanio A, Spina E, Di Rosa AE, Zappia M, Basile G, et al. Quetiapine versus clozapine: A preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease. Neurol Sci 2002 23 (Suppl. 2 S89 S90.
108. Arevalo GJ, Gershanik OS. Modulatory effect of clozapine on levodopa response in Parkinson's disease: A preliminary study. Mov Disord 1993 8 : 349 354.
109. Bennett JP Jr., Landow ER, Schuh LA. Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve Parkinsonism symptoms. Neurology 1993 43 : 1551 1555.
110. Durif F, Vidailhet M, Assal F, Roche C, Bonnet AM, Agid Y. Low-dose clozapine improves dyskinesias in Parkinson's disease. Neurology 1997 48 : 658 662.
111. Pierelli F, Adipietro A, Soldati G, Fattapposta F, Pozzessere G, Scoppetta C. Low dosage clozapine effects on L-dopa induced dyskinesias in Parkinsonian patients. Acta Neurol Scand 1998 97 : 295 299.
112. Morgante L, Epifanio A, Spina E, Zappia M, Di Rosa AE, Marconi R, et al. Quetiapine and clozapine in Parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 2004 27 : 153 156.
113. Waters C. Other pharmacological treatments for motor complications and dyskinesias. Mov Disord 2005 20 (Suppl. 11 S38 S44.
114. Henderson J, Yiannikas C, Graham JS. Effect of ritanserin, a highly selective 5-HT2 receptor antagonist, on Parkinson's disease. Clin Exp Neurol 1992 29 : 277 282.
115. Ikeguchi K, Kuroda A. Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs. Eur Arch Psychiatry Clin Neurosci 1995 244 : 320 324.
116. Avila A, Cardona X, Martin-Baranera M, Maho P, Sastre F, Bello J. Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial. J Clin Psychopharmacol 2003 23 : 509 513.
117. Golembiowska K, Dziubina A. Striatal adenosine A(2A) receptor blockade increases extracellular dopamine release following l-DOPA administration in intact and dopamine-denervated rats. Neuropharmacology 2004 47 : 414 426.
118. Bara-Jimenez W, Sherzai A, Dimitrova T, Favit A, Bibbiani F, Gillespie M, et al. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 2003 61 : 293 296.
119. Hillion J, Canals M, Torvinen M, Casado V, Scott R, Terasmaa A, et al. Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J Biol Chem 2002 277 : 18091 10897.